OMER · Omeros Corporation Common Stock
View on chartInsiders & Stakes
| Gregory A. Demopulos, MD Chairman, CEO & President | ▼ Sell | Tax Withholding | 1,469,308 Shares held | 2/18/2026 | View profile |
| Peter A. Demopulos, MD Director | ▲ Buy | Open Market | 208,516 Shares held | 11/15/2023 | View profile |
| Thomas J. Cable | ▼ Sell | Open Market | 35,067 Shares held | 8/20/2026 | View profile |
| Bumol Thomas F. Director | ▲ Buy | Grant | 10,000 Shares held | 9/12/2023 | View profile |
| Cancelmo Peter B VP, General Counsel | ▼ Sell | Open Market | 200 Shares held | 8/31/2026 | View profile |
| David J. Borges VP, Finance & CAO | ▼ Sell | Open Market | 0 Shares held | 9/23/2026 | View profile |
| HANISH ARNOLD C Director | ▼ Sell | Open Market | 0 Shares held | 8/27/2026 | View profile |
Transaction History
| David J. Borges | ▲ Buy | Option Exercise | 10,000 | $156K | 9/23/2026 |
| David J. Borges | ▼ Sell | Open Market | 10,000 | $210K | 9/23/2026 |
| David J. Borges | ▲ Buy | Option Exercise | 5,000 | $20K | 9/22/2026 |
| David J. Borges | ▲ Buy | Option Exercise | 5,000 | $15K | 9/22/2026 |
| David J. Borges | ▼ Sell | Open Market | 10,000 | $210K | 9/22/2026 |
| Cancelmo Peter B | ▲ Buy | Option Exercise | 25,000 | $74K | 8/31/2026 |
| Cancelmo Peter B | ▼ Sell | Open Market | 25,000 | $464K | 8/31/2026 |
| Cancelmo Peter B | ▲ Buy | Option Exercise | 25,000 | $74K | 8/28/2026 |
| Cancelmo Peter B | ▼ Sell | Open Market | 25,000 | $466K | 8/28/2026 |
| HANISH ARNOLD C | ▲ Buy | Option Exercise | 2,500 | $40K | 8/27/2026 |
| HANISH ARNOLD C | ▲ Buy | Option Exercise | 7,500 | $110K | 8/27/2026 |
| HANISH ARNOLD C | ▼ Sell | Open Market | 5,000 | $95K | 8/27/2026 |
| HANISH ARNOLD C | ▼ Sell | Open Market | 5,000 | $94K | 8/27/2026 |
| HANISH ARNOLD C | ▼ Sell | Open Market | 5,000 | $93K | 8/26/2026 |
| HANISH ARNOLD C | ▲ Buy | Option Exercise | 5,000 | $79K | 8/26/2026 |
| David J. Borges | ▼ Sell | Open Market | 906 | $17K | 8/24/2026 |
| David J. Borges | ▲ Buy | Option Exercise | 906 | $3K | 8/24/2026 |
| David J. Borges | ▲ Buy | Option Exercise | 5,906 | $23K | 8/21/2026 |
| David J. Borges | ▲ Buy | Option Exercise | 4,094 | $12K | 8/21/2026 |
| David J. Borges | ▼ Sell | Open Market | 10,000 | $190K | 8/21/2026 |
| Thomas J. Cable | ▲ Buy | Option Exercise | 7,500 | $15K | 8/20/2026 |
| Thomas J. Cable | ▲ Buy | Option Exercise | 7,500 | $29K | 8/20/2026 |
| Thomas J. Cable | ▼ Sell | Open Market | 15,000 | $277K | 8/20/2026 |
| David J. Borges | ▲ Buy | Option Exercise | 5,000 | $20K | 8/13/2026 |
| David J. Borges | ▼ Sell | Open Market | 5,000 | $85K | 8/13/2026 |
| Thomas J. Cable | ▲ Buy | Option Exercise | 7,500 | $81K | 5/22/2026 |
| Thomas J. Cable | ▼ Sell | Open Market | 7,500 | $87K | 5/22/2026 |
| Gregory A. Demopulos, MD | ▲ Buy | Option Exercise | 400,000 | $4.1M | 2/18/2026 |
| Gregory A. Demopulos, MD | ▼ Sell | Tax Withholding | 357,678 | $4.3M | 2/18/2026 |
| David J. Borges | ▲ Buy | Option Exercise | 30,000 | $92K | 1/13/2026 |
| David J. Borges | ▼ Sell | Open Market | 30,000 | $369K | 1/13/2026 |
| David J. Borges | ▼ Sell | Open Market | 30,000 | $382K | 1/12/2026 |
| Gregory A. Demopulos, MD | ▼ Sell | Gift | 600,000 | $0 | 10/13/2025 |
| Gregory A. Demopulos, MD | ▼ Sell | Gift | 300,000 | $0 | 10/13/2025 |
| Gregory A. Demopulos, MD | ▼ Sell | Gift | 300,000 | $0 | 10/13/2025 |
| Gregory A. Demopulos, MD | ▲ Buy | Open Market | 15,000 | $25K | 11/17/2023 |
| Peter A. Demopulos, MD | ▲ Buy | Open Market | 10,000 | $15K | 11/15/2023 |
| Gregory A. Demopulos, MD | ▲ Buy | Grant | 25,000 | $36K | 11/14/2023 |
| Gregory A. Demopulos, MD | ▲ Buy | Grant | 37,500 | $48K | 11/13/2023 |
| Bumol Thomas F. | ▲ Buy | Grant | 10,000 | $33K | 9/12/2023 |
| HANISH ARNOLD C | ▲ Buy | Option Exercise | 5,000 | $27K | 5/22/2023 |
| HANISH ARNOLD C | ▼ Sell | Open Market | 5,000 | $32K | 5/22/2023 |
| Thomas J. Cable | ▲ Buy | Option Exercise | 5,000 | $27K | 5/22/2023 |
| Thomas J. Cable | ▼ Sell | Open Market | 5,000 | $33K | 5/22/2023 |
| HANISH ARNOLD C | ▲ Buy | Option Exercise | 10,000 | $94K | 9/8/2021 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
Cantor Fitzgerald upgrades Omeros to Overweight with $22 target
Cantor Fitzgerald upgraded Omeros to Overweight and set a $22 price target, citing potential for its transplant drug. The stock recently hit a five-year peak, reflecting growing investor interest. This move aligns with broader analyst optimism, as the average target price stands at $27.50.
Cantor Fitzgerald upgrades Omeros to Overweight with $22 target. Cantor Fitzgerald upgraded Omeros to Overweight and set a $22 price target, citing potential for its transplant drug. The stock recently hit a five-year peak, reflecting growing investor interest. This move aligns with broader analyst optimism, as the average target price stands at $27.50.